Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Biognosys logo — Transforming life sciences with cutting-edge proteomics tech...

Biognosys

Transforming life sciences with cutting-edge proteomics technology and solutions

Founded 2008 Switzerland Schlieren, Switzerland 90 employees Series G Total: $9.03M Biotechnology, Health Care

General Information

Company Name Biognosys
Founded Year 2008
Location Switzerland Schlieren, Switzerland
Employees 90
Industries Biotechnology, Health Care
Funding Stage Series G
Social

BounceWatch is an independent company data service, not affiliated with Biognosys. To contact Biognosys, visit biognosys.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Biognosys compare?

A PDF of Biognosys and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Biognosys soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Biognosys

Biognosys is a Swiss biotechnology startup focused on transforming life sciences with cutting-edge proteomics technology and solutions. Since its establishment in 2008, the company has been revolutionizing disease diagnosis, treatment, and prevention through the decoding of the proteome. Biognosys offers a versatile portfolio of proprietary proteomics services, software, and kits, catering to pharmaceutical and biotechnology researchers as well as proteomics experts. The company's mass spectrometry-based proteomics solutions enable simultaneous quantification of thousands of proteins across thousands of samples, making it a leader in next-generation proteomics. From its global headquarters just outside of Zurich, Biognosys operates one of the largest high-end mass spectrometry laboratories worldwide for Large-Scale Discovery Proteomics contract research. As of the latest available information, Biognosys has received a Series G investment as of 12 August 2019. The company's global presence is evident through its extensive network of collaborators and distributors, with employees based across Switzerland, Europe, and the US, supporting a global customer base of life science researchers across industry and academia.

Business keywords: Proteomics, Mass Spectrometry, Drug Discovery, Clinical Research, Biomarker Discovery, Protein Analysis, Neuroscience, Oncology, Immunology, Rare Diseases, Chronic Diseases, Contract Research Services

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Series G Undisclosed -
12 Aug 2019
Series C $5.00M 1
PM Equity Partner
PM Equity Partner
12 Jul 2017
Series C Undisclosed -
13 Jan 2016
Debt Financing $1.00M -
12 Jan 2014
Venture Round Undisclosed -
07 Dec 2012
Series A $3.00M -
04 Nov 2011
Grant Fr.20.00K 1
Venture Kick
Venture Kick
11 Feb 2009
Grant Fr.10.00K 1
Venture Kick
Venture Kick
05 Nov 2008

Biognosys Alternatives & Competitors

View All Alternatives
Biognosys vs
Rapid Novor
Rapid Novor Canada

Decode the immune system by sequencing and quantifying antibody proteins. REmAb®, REpAb®, NovorIg™,...

Series A
56 employees
Biotechnology, Health Care
Biognosys vs
Pepscope
Pepscope The Netherlands

Kinome Activity Profiling

Venture round
3 employees
Biotechnology, Health Care
Biognosys vs
Micar Innovation (Micar21)
Micar Innovation (Micar21) Bulgaria

Micar Innovation - Drug Discovery Factory for novel drug molecules (structure based in silico drug d...

3 employees
AI, Biotechnology
View all alternatives

FAQ About Biognosys

Transforming life sciences with cutting-edge proteomics technology and solutions
Biognosys was founded in 2008.
Biognosys is headquartered in Schlieren, Switzerland.
Biognosys operates in Biotechnology and Health Care. Its work centres on Proteomics, Mass Spectrometry, Drug Discovery and Clinical Research.
Biognosys has approximately 90 employees.
Biognosys has completed 8 funding rounds, raising a total of $9.03M. The latest funding stage is Series G.
Top alternatives and competitors to Biognosys include Rapid Novor, Pepscope, Micar Innovation (Micar21), SomaScan, OmicEra Diagnostics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Biognosys and Rapid Novor are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Biognosys, https://bouncewatch.com/company/biognosys, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes